Irinotecan therapy—following a trail of breadcrumbs?

被引：0
作者：
Richard M. Goldberg
Bert H. O'Neil
机构：
[1] University of North Carolina,Division of Hematology and Oncology
来源：
Nature Reviews Gastroenterology & Hepatology | 2009年 / 6卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The optimal therapy for patients with metastatic and treatment-refractory colorectal cancer is controversial. Questions with regard to both the sequence and combinations of different drugs need to be answered by well-designed and adequately powered studies before the most appropriate option for second-line treatment for these patients can be defined.
引用
收藏
页码：507 / 509
页数：2
相关论文
共 15 条
  • [1] Mitry E(2009)Irinotecan as palliative chemotherapy for metastatic colorectal cancer: evolving tactics following initial treatment Int. J. Colorectal Dis. 24 605-612
  • [2] Lievre A(2005)Chemotherapy for advanced colorectal cancer: let's not forget how we got here (until we really can) Semin. Oncol. 32 35-42
  • [3] Bachet JB(2003)Irinotecan treatment in cancer patients with Oncology (Williston Park) 7 52-55
  • [4] Rougier P(2009) polymorphisms J. Clin. Oncol. 27 2457-2465
  • [5] O'Neil BH(2005)Predictive role of the Br. J. Cancer 92 1055-1062
  • [6] Goldberg RM(2007), Lancet 370 143-152
  • [7] Innocenti F(2008), and J. Clin. Oncol. 26 5326-5334
  • [8] Ratain MJ(2008) genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan J. Clin. Oncol. 26 2311-2319
  • [9] Cecchin E(2009)Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study J. Clin. Oncol. 27 672-680
  • [10] Van Cutsem E(2009)Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial N. Engl. J. Med. 360 563-572
12